Fortress Biotech - FBIO Competitors

Verastem (NASDAQ:VSTM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Which has higher valuation and earnings, VSTM or FBIO?

Fortress Biotech has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$2.60 million	32.03	-$73.81 million	-$0.38	-1.09
Fortress Biotech	$68.79 million	1.24	-$64.70 million	-$1.05	-0.71

Is VSTM or FBIO more profitable?

Verastem has a net margin of 0.00% compared to Fortress Biotech's net margin of -117.49%. Fortress Biotech's return on equity of -54.56% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	N/A	-124.62%	-69.85%
Fortress Biotech	-117.49%	-54.56%	-24.45%

Which has more risk and volatility, VSTM or FBIO?

Verastem has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.

Do analysts prefer VSTM or FBIO?

Verastem currently has a consensus price target of $4.25, suggesting a potential upside of 924.10%. Fortress Biotech has a consensus price target of $6.00, suggesting a potential upside of 700.00%. Given Verastem's higher possible upside, research analysts plainly believe Verastem is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer VSTM or FBIO?

In the previous week, Verastem had 6 more articles in the media than Fortress Biotech. MarketBeat recorded 12 mentions for Verastem and 6 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.05 beat Verastem's score of -0.03 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor VSTM or FBIO?

Verastem received 269 more outperform votes than Fortress Biotech when rated by MarketBeat users. However, 67.38% of users gave Fortress Biotech an outperform vote while only 66.55% of users gave Verastem an outperform vote.

Company	Underperform	Outperform
Verastem	Outperform Votes 585 66.55%	Underperform Votes 294 33.45%
Fortress Biotech	Outperform Votes 316 67.38%	Underperform Votes 153 32.62%

Do institutionals & insiders have more ownership in VSTM or FBIO?

60.6% of Verastem shares are owned by institutional investors. Comparatively, 27.9% of Fortress Biotech shares are owned by institutional investors. 2.9% of Verastem shares are owned by company insiders. Comparatively, 26.3% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Fortress Biotech beats Verastem on 9 of the 17 factors compared between the two stocks.